Hannay Michael Charles Ferguson 4
4 · BICYCLE THERAPEUTICS PLC · Filed Jul 7, 2026
Research Summary
AI-generated summary of this filing
Bicycle Therapeutics (BCYC) Chief Product & Supply Chain Officer Sells Shares
What Happened Michael Hannay, Bicycle Therapeutics' Chief Product & Supply Chain Officer, sold a total of 1,761 Bicycle Therapeutics (BCYC) shares in two open-market transactions to cover tax withholding on vested RSUs. On 2026-07-02 he sold 1,506 shares at a weighted average price of $4.27 for proceeds of $6,431 (prices ranged $4.26–$4.29). On 2026-07-06 he sold 255 shares at a weighted average price of $4.31 for proceeds of $1,099 (prices ranged $4.30–$4.31). Combined proceeds ≈ $7,530. These sales were reported on a Form 4 filed 2026-07-07.
Key Details
- Transaction types: Sales (open market) to satisfy tax withholding on RSU settlement (mandatory "sell-to-cover").
- Dates & prices:
- 2026-07-02 — 1,506 shares @ weighted avg $4.27; per-footnote range $4.26–$4.29; proceeds $6,431.
- 2026-07-06 — 255 shares @ weighted avg $4.31; per-footnote range $4.30–$4.31; proceeds $1,099.
- Total shares sold: 1,761; total proceeds ≈ $7,530.
- Shares owned after the transactions: Not specified in the information provided.
- Footnotes: F1 — sale mandated by award agreement to cover statutory tax withholding (not a discretionary sale). F2/F3 — reported prices are weighted averages with per-trade price ranges; detailed per-price breakdown available on request.
- Filing: Form 4 filed 2026-07-07 reporting both trades.
Context
- These sales were sell-to-cover transactions tied to RSU vesting; such mandated sales are common and typically do not signal a change in insider sentiment. They differ from discretionary sales (which might be more informative) and from purchases (which are often seen as a stronger bullish signal).
Insider Transaction Report
Form 4
Hannay Michael Charles Ferguson
CHIEF PROD & SUPPLY CHAIN OFF
Transactions
- Sale
Ordinary Shares
[F1][F2]2026-07-02$4.27/sh−1,506$6,431→ 94,630 total - Sale
Ordinary Shares
[F1][F3]2026-07-06$4.31/sh−255$1,099→ 94,375 total
Footnotes (3)
- [F1]Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.26 to $4.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.30 to $4.31 inclusive.
Signature
/s/ Travis Thompson, Attorney-in-Fact|2026-07-07